Search Results

23 Results for "levicept".

Sort By

Press Releases

Levicept Announces the Appointment of James Sandy as Chief Development Officer

February 4, 2026
·
3 min read
Press Releases

Levicept Announces FDA Acceptance of IND Application for LEVI-04, a Potentially Disease-Modifying Treatment for Osteoarthritis

January 20, 2026
·
2 min read
Press Releases

Levicept Presents New Data Suggesting a Novel Neurotrophin-3 Inhibitor, LEVI-04, May Modify Disease and Improve Symptoms in Osteoarthritis

October 27, 2025
·
5 min read
Press Releases

Levicept to Present Key New Data from Phase II Trial of LEVI-04, a Novel Neurotrophin-3 Inhibitor, at ACR Convergence 2025

September 25, 2025
·
3 min read
Press Releases

Levicept to Present Further Analysis from Phase II Trial of Novel Neurotrophin-3 Inhibitor, LEVI-04, at EULAR

June 12, 2025
·
4 min read
Press Releases

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, at 2025 World Congress on Osteoarthritis

April 28, 2025
·
4 min read
Business

Levicept Appoints Eliot Forster as CEO

Levicept Ltd, a biotechnology company focused on the development of LEVI-04, a first-in-class treatment for chronic pain indications, announces the appointment of Eliot Forster as CEO.

November 30, 2023
·
3 min read
Drug Development

Levicept Completes Recruitment in Phase II Clinical Trial of Neurotrophin Modulator LEVI-04

Levicept Ltd announces it has completed recruitment in its Phase II clinical trial of LEVI-04, a novel neurotrophin-modulating biological agent.

December 13, 2023
·
3 min read
Press Releases

Levicept to Present Phase II Data at ACR Convergence 2024

October 28, 2024
·
2 min read
Press Releases

Levicept Presents Positive Phase II Data for Novel Neurotrophin-3 Inhibitor, LEVI-04, for Treatment of Patients with Moderate to Severe Osteoarthritis at ACR Convergence 2024

November 14, 2024
·
3 min read